Getting answers on tariffs, China and Trump: What we learned from Q2 earnings

After three weeks of corporate earnings reports, we’ve got a roundup of news and analysis taking in all of the biotech and pharma companies that gave updates. We’ll dig into what big pharma companies are saying about the Trump administration’s tariff, pricing and regulatory moves, how companies are talking about China and what we learned about closely watched results from a few key companies like Lilly and Novo, a pain drug failure and how big pharma is positioning itself for its patent cliff.